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INTRODUCTION 
The Food and Drug Administration’s 2015 approval of Flibanserin, a drug intended to 
treat female sexual desire disorder, solidifies the classification of low female libido as a medical 
dysfunction. Initially hailed as innovative by the medical community for its attention to an 
alleged women’s1 health issue, Flibanserin has now come to represent the medical community’s 
commodification and objectification of female sexualities—exemplifying the way in which 
female bodies are disproportionately subjected to the medical gaze and public scrutiny. Although 
a drug now exists to treat the alleged disorder, the medical and scientific communities lack 
consensus on what constitutes low libido and how this disorder should be quantified (Wood, 
Koch, & Mansfield, 2006). This disorder’s prevailing diagnostic criteria lie within a woman’s 
own sexual discontentment, highlighting the ambiguity of low female libido (American 
Psychiatric Association, 2013). While providing women with the power to recognize this 
disorder in themselves appears beneficial, this makes it difficult to ascertain whether women 
seek medical intervention for low libido because they want to want more sex or because they 
have been prompted by external sociocultural factors that cast their libidos as dysfunctional—
such as unsatisfied romantic partners desiring additional sexual interactions. If this disorder is 
primarily diagnosed by assessing women’s own frustrations with their lack of desire, but their 
lack of desire only frustrates them because it upsets their partners, can these women really be 
said to have a medical dysfunction? This seems to force women to shoulder the blame for their 
partners’ sexual dissatisfaction. Answers to this question and the associated problems it raises 
have been rendered invisible within the medical arena, as such answers have the power to 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 I do recognize that not all women have vulvas and vaginas and not all people with vulvas and 
vaginas identify as women. However, I have chosen to utilize the term “women” here and 
throughout the rest of this thesis to refer to cis-gender women in order to mirror the language 
utilized within the medical discourse on female sexual desire disorder.  
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destabilize the very foundation upon which this alleged dysfunction has been built. Utilizing 
social constructionist theory of sexual normalcy, this thesis will problematize biomedical 
conceptualizations of female sexual desire and will underscore the ways in which medicalization 
of low female libido lends authority to and is legitimized by predominant heteronormative, 
patriarchal sexual norms. The medicalization of this phenomenon lends credence to the 
problematic notion that frequent sex is the bedrock of a healthy relationship and that women 
must prioritize their male partners’ sexual needs—transforming such questionable beliefs into 
seemingly unquestionable truths. Rather than addressing sociocultural influences that impact 
women’s experiences of desire or deconstructing the problematic understanding of sex’s role in 
romantic partnerships, medicalization solely legitimizes the idea that women’s sexualities—and 
not the narrow constructions of normalcy with which they must attempt to align themselves—
exist as the primary issue necessitating alteration.   
SIGNIFICANCE 
The authoritative role accorded to doctors and scientists in Western society arms the 
medical and scientific communities with the power to shape general understandings of sex, 
sexuality, and sexual dysfunction. As feminist scholar Leonore Tiefer notes, “[t]he process of 
medicalization, promoted by industry, media, health experts, and conservative political actors, 
produces sexual values, language, classification systems, and authorities, and profoundly shapes 
the popular view of sexuality, despite a culture full of diverse sexual voices” (Tiefer, 2002). 
Medicalization, therefore, absolutely demands critique. The process of medicalization often 
employs a myopic focus to depict health problems, portraying dysfunctions as byproducts of 
failed physiological processes (Conrad, 2007). While ensuring that women receive the health 
care that they seek is important, it is also important to recognize that medicalization is not a 
process inherently free from bias. One must not forget that the process of medicalization occurs 
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in an arena that has historically addressed women’s health in a manner that not only fails to 
empower women, but also works to serve men and exert increasing social control over women’s 
bodies and actions.   
 Rather than analyzing the sociocultural, political, or economic factors that may influence 
and construct notions of female sexual desire, the medical community has largely situated desire, 
and problems with desire, exclusively within the body, transforming women’s bodies into sites 
of medical scrutiny. The way that low libido in women has been medicalized reflects and 
reinforces patriarchal notions of sexual normalcy, raising questions as to whether its 
medicalization advances women’s health. It is crucial to challenge the existing misinformation 
about female sexual desire to avoid normalizing the consumption of drugs that attempt to treat 
what might simply be normal variations in human functioning and to avoid pathologizing 
women’s refusal to engage in sexual intercourse.  
BACKGROUND: HISTORICAL RELEVANCE, DIAGNOSTIC CRITERIA, AND 
CONVENTIONAL APPROACHES TO CONCEPTUALIZING DESIRE  
This section will provide a brief overview of medicalized female sexuality’s historical 
roots, low female libido’s prevalence and diagnostic criteria, and conventional understandings of 
female sexual desire. Although brief, this historical relevance proves necessary as it 
demonstrates the ways in which women’s bodies have long been objects of medical scrutiny.  
Additionally, understanding low female libido’s prevalence and diagnostic criteria reveals the 
number of women that could potentially be diagnosed as sexually dysfunctional. This paves the 
way for questions as to how a phenomenon afflicting the majority of a population comes to be 
considered abnormal and dysfunctional. Furthermore, the conventional conceptualizations of 
female sexual desire that I outline are those that the medical and scientific community has relied 
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upon to designate low libido as a threat to health. Thus, understanding these conceptualizations 
allows for a more comprehensive approach to examining medicalized female sexualities.   
Historical Relevance 
The medicalization of an alleged female sexual dysfunction is not a novel phenomenon 
unique to low female libido. In fact, framing perceived female sexual problems as medical 
dysfunctions possesses deeply historical roots.  In the early 20th century, Sigmund Freud began 
to diagnose women incapable of achieving orgasm via vaginal penetration alone with a disorder 
he referred to as “frigidity,” suggesting that their failure to reach climax in this way existed as a 
medical problem (Koedt, 1973). According to Freud’s portrayal of female sexual pleasure, 
sexual pleasure is initially associated with the clitoris, but as girls mature and begin having 
penile-vaginal sex with men, this association should shift to the vagina. This is because the 
vagina was said to be capable of producing orgasms that are more mature compared to those that 
the clitoris produced (Koedt, 1973). However, very few women are able to reach orgasm from 
penile-vaginal penetration alone; only about 7% of women are able to climax in this way 
(Wallen & Lloyd, 2011). Furthermore, sex researchers believe that what has been dubbed the 
“vaginal orgasm” is actually a mere variation of the clitoral orgasm (Wallen & Lloyd, 2011). The 
vagina and the clitoris are not entirely separate entities and beliefs that they are typically stem 
from misunderstandings regarding the clitoris’s actual size. Despite the fact that only part of it is 
externally visible, the clitoral organ actually surrounds the vagina, urethra, and anus. In fact, 
Yale Urologist Amichai Kilchevsky argues that the “G-Spot” is just an extension of the clitoris 
inside the vagina (Kilchevsky et al., 2012). For some women, vaginal penetration is able to 
stimulate the clitoris and provide the friction necessary for orgasm. For most women, however, 
this is not possible and direct stimulation of the clitoris is typically necessary.  
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In response to the rigid restraints imposed upon women’s sexualities in the early 1900s 
and the centuries prior, myriad second wave feminists in the late 1960s began to espouse the idea 
that women’s freedom and liberation could not be achieved without sexual freedom and 
liberation, launching what is now referred to as the Sexual Revolution. This movement 
challenged Freud’s misconceptions regarding the female orgasm and encouraged women to 
engage in sexual activities that were most pleasurable to them—regardless of whether or not they 
aligned with certain sociocultural expectations of sexual normalcy. During this time, sexual 
liberationists urged women to enjoy sex, have multiple sexual partners, engage in sexual 
experimentation, and initiate sexual advances (Greer, 1971). Additionally, this movement’s 
efforts allowed for the development of the birth control pill, the legalization of abortion, 
normalization of premarital sex and pornography, and encouraged the acceptance of non-
heterosexual sexualities. This movement encouraged women to shed the shame they harbored 
about their bodies and sexualities and suggested that it was not only possible, but also necessary 
for women to have sexual encounters that satisfied them just as much as it satisfied their male 
partners. Although women continue to face shame for expressing their sexuality in contemporary 
America, the Sexual Revolution did work to challenge the restrictive notion that women could 
not be active sexual subjects in their own lives in the same ways that men were.  
The Prevalence of Female Sexual Desire Disorder 
Despite the sexual liberation movement’s apparent claims that all women exist as 
fundamentally sexual people, recent research reveals that low libido or lack of sexual interest 
exists as the most common sexual problem that Western women face (Kingsberg & Woodard, 
2015). Juliet Richters and colleagues’ large-scale Australian national survey discovered that 54.8 
percent of women reported low sexual desire and lacked interest in having sex (Richters et al., 
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2003). A singular cause for this lowered female libido remains elusive and impossible to 
pinpoint, as sexual desire exists as a vastly complex phenomenon. As Jennifer Drew notes in her 
article “The Myth of Female Sexual Dysfunction and its Medicalization,” sexual desire remains 
confounded by various complexities. She writes, “[l]ack of sexual desire in women can be 
caused by complex inter-linked factors such as socio-cultural, economic, psychological, narrow 
gender roles and beliefs which influence women's and men's sexual expectations (Drew, 2003).  
DSM-5 Conceptualization of Female Sexual Desire Disorder 
 Despite its complexities, myriad attempts have been made to examine and understand 
this apparent disorder, first garnering low female libido its own section in The Diagnostic and 
Statistical Manual of Mental Disorders in 1980 (American Psychological Association, 2009). 
The criteria used to diagnose and characterize this disorder have undergone several alterations 
since its inception in the 80s, both reflecting and influencing cultural beliefs regarding the female 
body. According to the DSM-5 (5th ed.; DSM-5; American Psychiatric Association, 2013), 
Sexual Interest/Arousal Disorder—the umbrella term under which female sexual desire disorder 
is categorized—exists as a disorder characterized by a “lack of, or significantly reduced, sexual 
interest/ arousal” (American Psychiatric Association, 2013). Despite its title, low female libido 
exists as the most common name for this disorder. Additionally, the DSM-5’s definition of this 
dysfunction explicitly excludes low female libido that exists as a result of physical trauma or 
medication induced causes, casting sexual desire disorder as a dysfunction in its own right, rather 
than a side effect (American Psychiatric Association, 2013).  Although the DSM-5 contains a 
rather concise set of symptoms that seem to lend to an ease in diagnosis, research reveals that the 
medical and scientific community not only lack a consensus regarding the best ways in which to 
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understand and quantify this disorder, but also exhibit problematic understandings of “normal” 
female sexual desire and functioning (Segal, 2015).  
Although the DSM-5 officially refers to what I call female sexual desire disorder as 
“female sexual interest/ arousal disorder,” it goes by various different names in scholarly 
literature. These names include female sexual desire disorder, female hypoactive sexual desire 
disorder and low female libido. The multiple terms utilized to discuss female sexual interest/ 
arousal disorder seem to be reflective of the medical and scientific communities’ failure to agree 
on its specifications. Furthermore, the official name “female sexual interest/ arousal disorder” is 
both misleading and confusing, as it actually refers to two distinct disorders. The DSM-5’s 
female sexual interest/arousal disorder represents a merging of two formerly separate sexual 
dysfunctions: female hypoactive sexual desire disorder and female arousal disorder. The former 
is related to low female libido, while the latter refers to a physical inability to become aroused. 
For purposes of clarity and consistency, and because I find the DSM’s label vague and deceptive, 
I will primarily refer to this disorder as female sexual desire disorder (FSDD), low libido, or low 
sex drive. Female sexual desire disorder is the term most often used in both relevant medical 
literature and feminist critiques of such literature. I decided to utilize the term female sexual 
desire disorder when referencing the medicalized conceptualizations of this phenomenon due to 
its prevalence in scholarly discourse. I also decided to utilize the terms low libido and low sex 
drive because they are widely used by both laypeople and scholars alike.  
Conventional Understandings of Female Sexual Desire 
A single, quantifiable definition of low female libido does not exist. It is instead left up to 
the individual woman to determine if her libido is low. Thus, low libido is cast as a “you know it 
when you have it” type of problem. This, however, has not prevented physicians from treating 
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these highly individualized experiences as medical problems. In order to define a disorder whose 
symptoms are predicated upon a lack of desire, the meaning of desire must first be established. 
However, the DSM-5—and other clinicians and researchers who aim to understand and address 
this disorder—have yet to definitively do so. Female sexual desire’s definition—or lack 
thereof—is the first obstruction that those aiming to understand this phenomenon face. One 
might assume that a quantifiable definition exists due to Flibanserin’s creation; however, this is 
not the case. Sexual desire remains a highly subjective experience that lacks consistent cognitive, 
physiological, or behavioral referents for all women (Meana, 2010; McCabe and Goldhammer, 
2013). The research regarding desire that currently exists aims to classify and understand female 
desire using a biological conceptualization, an approach that medicalized constructions of female 
sexual desire disorder rely upon to cast low libido as a threat to health.  
The most common model utilized to formulate understandings of female sexual desire is 
the Human Sexual Response Cycle—also known as the Linearity Model. This model refers to 
the theoretical model regarding sexual response first described by Masters and Johnson in 1966 
(Masters & Johnson, 1966). This model understands female desire as a physically driven 
characteristic with easily distinguishable phases that proceed in a direct linear fashion. The 
phases it delineates are synonymous with those outlined in the male model of sexual response: 
excitement—which refers to physical arousal resulting from erotic stimuli, plateau, orgasm, and 
resolution (Hayes, 2011). This model suggests that sexual desire is a physical longing for or 
motivation to engage in sexual activity.  It conflates physical arousal with sexual desire and fails 
to explicitly elucidate how desire comes into being in the first place. Because it situates desire as 
a physiological process that occurs within the body as the result of direct erotic stimulation and 
because this model continues to dominate the medical and scientific discourse on female sexual 
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desire, physicians and scientists are able to situate problems with desire as bodily malfunctions. 
(Wood, Koch, & Mansfield, 2006).  
Despite the fact that an adequate definition of desire remains elusive, pharmaceutical 
intervention aiming to combat this alleged disorder has recently been introduced into the public 
arena (FDA News Release, 2015). This new drug is often incorrectly referred to as the “Pink 
Viagra” despite having no relationship to the erectile dysfunction drug. Viagra works by acting 
on the erectile tissue within the penis to increase blood flow in men with circulatory problems. 
The men utilizing Viagra do not have a problem in terms of sexual desire; the problem instead 
lies within their bodies’ responses to that desire (Clayton et al., 2010). The available research 
regarding low female libido reveals that the problem lies within the existence—or lack thereof—
of desire itself, not within their bodies’ responses to desire. Flibanserin aims to correct 
neurochemical imbalances by providing the brain with a mix of alleged desire-inducing 
chemicals (Segal, 2015). According to information provided by the drug’s producer, Sprout 
Pharmaceuticals, “Flibanserin increases dopamine and norepinephrine (both responsible for 
sexual excitement) while transiently decreasing serotonin (responsible for sexual 
satiety/inhibition) in the brain's prefrontal cortex” (Sprout Pharmaceuticals, 2015). 
 Additionally, research reveals that Flibanserin fails to work as the desire-inducing, magic 
pill that the pharmaceutical industry has portrayed it to be, as it possesses a minimal impact on 
female desire (Jasper et al., 2016). According to FDA analysis of Flibanserin, only eight to 
thirteen percent of women who take the drug will see improvement over the placebo. This 
improvement is defined as having .5 more sexually satisfying encounters per month (Gellad, 
Flynn, and Alexander, 2015). While having more sex might be the ultimate goal of those who 
take this drug, engaging in sexual intercourse does not necessarily mean that desire for the 
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encounter actually exists, as I will demonstrate in following sections. Furthermore, the FDA had 
rejected the drug twice prior to its approval in 2015 and its approval was the result of powerful 
marketing, rather than any actual improvement to the drug’s efficacy or safety. (Belluz, 2015). In 
2013, the drug’s maker, Sprout Pharmaceuticals, launched the “Even the Score” campaign. 
“Even the Score” advocates for the creation of sexual pharmaceuticals for women because, 
according to the campaign, such drugs are available to men. The campaign’s website states, 
“[w]ith 26 FDA-approved treatment options for men’s sexual dysfunction and only 1 for women, 
we have a long way to go in recognizing the important role sexual desire plays in a woman’s 
overall health.” (Even the Score, 2015). By casting a lack of sexual pharmaceuticals for women 
as a matter of inequality, as this campaign does, it presumes that sexual pharmaceuticals are a 
necessarily positive entity without considering medicalization’s negative ramifications. 
Providing both men and women with equal access to deleterious drugs is equality in name alone; 
it does nothing to truly advance the feminist movement or women’s rights. Additionally, the 
information on the campaign’s website is misleading. Flibanserin is the only drug of its kind on 
the market. The sexual dysfunction drugs available to men exist to treat physical inability to 
become aroused, whereas Flibanserin, as previously explained, is not intended to supplement 
physical arousal in women.  
As demonstrated in this section, medicalized conceptualizations of female sexuality are 
not new or unique to female libido. Women’s sexualities have been the subject of medical 
scrutiny for decades and understanding this history demonstrates the ways in which medicine 
exists as a double-edged sword that has the power to both benefit and disadvantage women.  The 
biomedical approach to understanding sexual desire has dominated the field of low libido 
research, firmly situating this problem under the rubric of health. Despite the plethora of existing 
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biomedical research on female sexual desire, a single definition of low libido does not yet exist. 
So while low libido is reported to be a common problem for women, the medical and scientific 
communities still lack consensus on what low libido actually is. Although low libido remains 
difficult to define, pharmaceutical intervention has already been introduced aiming to combat 
this alleged problem. The pharmaceutical industry has created Flibanserin in an attempt to 
answer questions concerning how to change low libido in women, but the question of what low 
libido actually is and whether it truly needs to be changed remains unanswered. As evidenced 
Flibanserin’s reported inefficacy, we cannot respond to a perceived problem until we fully 
understand what the problem actually is. Prior to creating additional pharmaceuticals to combat 
this alleged problem, an assessment as to whether or not low female libido should even be 
classified as a medical dysfunction proves necessary. Continuing to create drugs to treat a non-
existent sexual dysfunction will not only do little to alter the perceived problem, but will also 
continue to reinforce the idea that women must engage in sex in a certain way in order to align 
with societal expectations of sexual normalcy.  
METHODS 
This thesis utilizes feminist theory to critique the predominant biomedical and 
pharmaceutical research on female sexual desire disorder and utilizes feminist ethnomethodology 
to draw upon women’s personal narratives to examine low female libido as lived experience. 
This approach, as utilized by Brianne Fahs in her text Performing Sex: The Making and 
Unmaking of Women’s Erotic Lives, involves speaking directly to women about their own sexual 
experiences to better understand how they conceptualize and internalize sociocultural meanings 
of sexual normalcy (Fahs, 2011). Focusing on women with low libidos’ personal narratives 
demonstrates that a woman’s sexual desire cannot be examined separately or disentangled from 
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the restrictive sociocultural forces that dictate norms regarding sexuality, intimacy, gender 
differences, romance, and even happiness—among myriad other things. 
Additionally, my thesis relies upon social constructionist approaches to conceptualize 
sexuality and sexual desire. While myriad scholars continue to debate the specifications and 
mechanisms of social constructionism as it relates to sex, these theorists tend to agree that social 
institutions—such as mass media, religious organizations, political parties—and social 
interaction enact norms that signal and shape sexuality and sexual behavior (Schwartz and 
Rutter, 1998; Foucault, 1978; Lorber, 1994). In regards to social constructionist theories of 
sexuality, feminist scholars Pepper Schwartz and Virginia Rutter state, “[t]he sexual customs, 
values, and expectations of a culture, passed on to the young through teaching and by example, 
exert a powerful influence over individuals…Even with the nearly infinite variety of sexuality 
that individual experience produces, social circumstances shape sexual patterns” (Schwartz and 
Rutter, 1998). This quote succinctly highlights my theory of sexuality; social context exists as a 
powerful force that shapes our own understandings of the world and our position within it.  
While I do critique biologically essentialist approaches to understanding how sexual 
desire comes into being and argue that sexual normalcy is largely a social construction in this 
thesis, I do not outright reject all claims that biology may have some influence in the experience 
of sexual desire. I would be welcome to an approach that understands sexuality as a byproduct of 
both social and biological circumstances. The reason I choose to focus my efforts on illuminating 
the complex social forces that influence desire—rather than an integration of biology and social 
context—is because the social as been rendered entirely invisible in the medicalization of sexual 
desire. Furthermore, framing sexuality as biological and natural tends to rigidly categorize 
certain sexualities as either normal or abnormal (Foucault, 1978). Biological explanations have 
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been exclusively privileged and it is time we recognize that what goes on outside of our bodies 
matters just as much and certainly influences what happens within them. I want to be clear: in 
asserting that sex is a byproduct of complex social forces I do not mean to say that sexuality is a 
choice and I am in no way suggesting that social constructs are not “real”. To quote Schwartz 
and Rutter, “[t]he social world is as much a fact as in people’s lives as the biological world” 
(Schwartz and Rutter, 1998).  
The primary research method for this thesis is qualitative data garnered from ten semi-
structured interviews with women who self identify as having low libido. Semi-structured 
interviews are commonly used by feminist ethnographic researchers and are often considered the 
best way to collect data that “captures the multitude of subjects’ views of a theme so that the 
researcher comes to see the respondents’ complex social world” (Wambui, 2013; Denzin & 
Lincoln, 2000). I chose to utilize this approach so as to analyze women’s experiences from their 
own perspectives—research that would challenge the ways that the predominant biomedical 
research conceals women’s subjectivity and silences their voices. I did not specify what low 
libido meant exactly when soliciting participants and in conversation with my interviewees, as it 
is subjective and differs for each individual. That is, the “lowness” of low libido is a thing that 
has been constructed and lacks definitive referents for all women. There is no single clear-cut 
definition of low libido and hearing about how these women conceptualize the meaning of this 
term is part of what my research aimed to discover.  
I utilized the popular, well-trafficked Reddit discussion board titled “Sex” to recruit 
subjects. This message board—or subreddit according to the website’s parlance—is the only 
website whose moderators approved my request to conduct research. “Sex” provides a platform 
for civil discussions and questions about sex and bans all pornographic material and erotic text. 
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This specific forum has 669,526 subscribers and has about 1,500 active readers at any given 
time, ensuring that my request for research participants reached a significant number of 
individuals. To garner participants, I posted two threads one month apart from each other 
signifying the characteristics I was looking for in subjects. The characteristics I signified 
required that women be older than 18 and identify as having low libido. Although I did not 
exclude non-heterosexual women from participating in my research, all but two of my ten 
participants identified as heterosexual. The ten women I spoke with ranged in age from 18 to 34-
years-old. They each differed in the number of sexual partners that they had had and their current 
relationship status. I did not ask about race and class in the interview or solicitation process.  
I utilized several questions to guide my interviews and while direction of the 
conversation often differed as a result of an individual respondent’s answers, I made sure to 
incorporate key areas for discussion in each interview. The questions I included in each 
interview included asking these women what sexual desire means to them, how they came to 
understand their libido as low, and if their low libido bothers and if so, what bothers them most 
about it. I avoided asking questions that would elicit one word, yes or no answers in order to 
keep conversation flowing.  
I conducted ten interviews total. Three interviews occurred via phone, five occurred via 
email, one took place via Skype Instant Message, and one took place via text message. The seven 
women who chose not to speak on the phone indicated fear that their partners or roommates 
might hear our conversation, highlighting the fact that low libido is considered embarrassing and 
taboo.  
In addition to conducting interviews that prioritized women’s lived experiences, I also 
conducted a review of the current literature on female sexual desire disorder. This consisted of an 
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interdisciplinary examination of peer-reviewed literature from various fields. These fields 
include—but are not limited to—biomedicine, feminist theory, sociology, and sexual 
anthropology. Utilizing various disciplines allowed for a more comprehensive understanding of 
female sexual desire disorder and the ways in which this illness has been constructed medically, 
socially, and culturally. Databases such as JStor, GenderWatch, Gender Studies, PubMed, 
Sociological Abstracts, and PsychINFO were utilized in order to conduct research. Vanderbilt’s 
Discover Library database was utilized in addition to these databases, as it provided less 
specified results and articles from various disciplines. Because this alleged disorder exists as a 
recently medicalized illness, searches were not limited to specified time periods. I began my 
research with an examination of the DSM-5’s depiction of sexual dysfunctions to better 
understand current conceptualizations of this disorder. I then began researching female sexual 
desire disorder on the aforementioned databases. Upon collecting this data, I examined these 
articles for common themes, recognizing the problematic definitions utilized in medical literature 
and this literature’s lack of discussion of external stressors and gender role assumptions. I then 
began research on feminist critiques of both the medicalization of female sexual desire and of 
medicalization more generally. I ultimately drew upon common themes to underscore the ways 
in which the medical community’s framing of female sexual desire disorder relies upon 
patriarchal notions of women’s bodies and sexualities.  
In addition to a review of the current literature on female sexual desire disorder, I aimed 
to craft research that analyzed women’s experiences from their own perspectives—research that 
would challenge the ways that the predominant biomedical research conceals women’s 
subjectivity and silences their voices. In order to collect data that prioritizes women’s lived 
experiences, I conducted semi-structured interviews with women who self identify as having low 
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libido. I did not specify what low libido meant exactly, as it is subjective and differs for each 
individual. What might be considered low for one woman could be high for another. 
I utilized the popular, well-trafficked Reddit discussion board titled “Sex” to recruit 
subjects. This message board—or subreddit according to the website’s parlance—is the only 
website whose moderators approved my request to conduct research. “Sex” provides a platform 
for civil discussions and questions about sex and sexual relationships more generally and bans all 
pornographic material and erotic text. This specific forum has 669,526 subscribers and has about 
1,500 active readers at any given time, ensuring that my request for research participants reached 
a significant number of individuals. To garner participants, posted two threads one month apart 
from each other signifying the characteristics I was looking for in subjects. The characteristics I 
signified required that women be older than 18 and identify as having low libido. Although I did 
not exclude non-heterosexual women from participating in my research, all but two of my ten 
participants identified as heterosexual. The two non-heterosexual participants identified as 
bisexual. The high number of heterosexual participants reinforces the notion that male sexual 
values continue to shape understandings of sexual normalcy. Straight women and women who 
sleep with men seem to be more concerned with having low libido because a lowered sex drive 
fails to align with what has been deemed normal in the context of heterosexual relationships. 
  I conducted ten interviews total. Three interviews occurred via phone, five occurred via 
email, one took place via Skype Instant Message, and one took place via text message. The seven 
women who chose not to speak on the phone indicated fear that their partners or roommates 
might hear our conversation, highlighting the fact that low libido is considered embarrassing and 
taboo.  
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This thesis also includes pilot research conducted in my graduate-level research methods 
course. This pilot research is comprised of both participant observation and two semi-structured 
interviews. This initial pilot research possesses significance as it facilitated my decision to 
interview women who actually live with low libido. I crafted this research in two seemingly 
contrasting arenas: a women’s sexual health clinic and an adult entertainment store. At the 
women’s sexual health clinic, I interviewed one of their nurse practitioners. At the adult 
entertainment store, I spoke with the store’s manager, observed the environment, and noted the 
products they offered.  While I initially worried about the stark differences I expected to find, the 
distinctions between these two locations presented a crucial source of additional analysis to 
accompany and further inform my thesis research. 
CRITIQUES OF MEDICALIZED SEXUALITIES, RIGID DEFINITIONS OF SEXUAL 
NORMALCY, AND THE PROBLEMATIC IMPLICATIONS OF BIOMEDICAL 
CONCEPTUALIZATIONS OF DESIRE: A REVIEW OF CURRENT FEMINIST 
LITERATURE 
In this section, I will underscore the relevant feminist critiques directed at the information 
contained within my background section. This will work to underscore the ways in which female 
sexual desire disorder merely represents an additional attempt to exert social control over 
women’s bodies and define sexual normalcy according to men’s pleasure. Additionally, this 
section will reveal the problematic implications associated with the predominant biomedical 
conceptualizations of female sexual desire. This will highlight the myriad faults within the very 
foundation upon which this medical disorder has been built. 
Significance of Medicalized Low Female Libido’s Historical Roots and the Issues They 
Raise 
Freud’s medicalization of Frigidity is not merely problematic due to its scientific 
inaccuracies regarding the vaginal orgasm. It proves problematic due to the fact that it exists as a 
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rather transparent attempt to define standard heterosexual sexual practices according to what is 
most pleasurable for men. This demonstrates that, historically, medicalization has been a tool 
utilized to serve male interests, rather than a tool intended to advance women’s wellbeing. As 
Feminist scholar Anne Koedt notes in her essay “The Myth of the Vaginal Orgasm,” 
medicalizing frigidity was merely an attempt to pathologize sexual acts that failed to prioritize 
male pleasure (Koedt, 1973). Penile-vaginal penetration allowed men to experience the friction 
necessary to reach climax; sex acts prioritizing the clitoris, however, need not even involve the 
penis. Because orgasms achieved via clitoral stimulation had the power to render the penis 
unnecessary, deeming this method of orgasm immature and representative of dysfunction 
ensured that women would conform to the sexual acts that benefited men. Essentially, acts that 
prioritize men’s pleasure became the norm under the guise that vaginal penetration could 
produce a similar, more mature level of pleasure in women. Despite the fact that the vaginal 
orgasm is no longer considered a more mature form of climax, myriad men continue to operate 
under the belief that all women are capable of reaching orgasm via penetrative penile-vaginal 
sex. Analogous to the medicalization of frigidity, the medicalization of female sexual desire 
disorder works to police women’s sexuality in a way that prioritizes male pleasure and restricts 
the definition of sexual normalcy. And since the myth of frigidity has persisted for almost 100 
years, this does not bode well for the potential persistence of medicalized low libido. 
Although the rise of sexual liberation in the 1970s has challenged the aforementioned 
problematic conceptions of sexual pleasure set forth by Freud and has provided women with an 
increased ability to express their sexualities, the rhetoric characterizing such liberation—both 
during the 1970s and in the decades since—has crafted rather narrow definitions of what sexual 
freedom ought to look like. Encouraging women to explore their sexuality certainly represented a 
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social volte-face from the existing narrow gender roles available to women at the time; however, 
it failed to dismantle the power imbalances between men and women in the sexual sphere and 
reinforced patriarchal assumptions regarding female sexuality (hooks, 1984). Sexual liberation’s 
increased emphasis on engaging in more sexual intercourse rendered those who lacked a desire 
for such encounters invisible. Feminist theorist bell hooks highlights the limitations of sexual 
liberation in her 1983 text Feminist Theory: From Margin to Center. Hooks writes, “ [t]o act 
sexually is deemed natural, normal; to not act, unnatural, abnormal…Women’s liberationists’ 
insistence that women should be sexually active as a gesture of liberation helped free female 
sexuality from the restraints imposed upon it by repressive double standards, but it did not 
remove the stigma attached to sexual inactivity. Until that stigma is removed, women and men 
will not feel free to participate in sexual activity when they desire” (hooks, 1984). The 
medicalization of female sexual desire disorder and the associated rhetoric of gender equality 
often utilized in discussions regarding the creation of a pill to treat such a disorder demonstrate 
that—like characterizations of sexual liberation in the 1970s—not having sex is still considered 
abnormal; women can be sexually liberated as long as sexual liberation means that they want to 
have often, initiate sexual encounters, and continue to engage in heterosexual sex whenever their 
partners want.  
Critiques of Biomedical Conceptualizations of Female Sexual Desire 
As previously discussed, the Human Sexual Response Cycle—or the Linearity Model—
continues to dominate medical and scientific research on female sexual desire. While this model 
for understanding sexuality appears straightforward and might seem to lend to an ease in 
identifying sexual problems, feminist theorists have critiqued this model and deemed it an 
inadequate explanation for female sexuality. The Human Sexual Response Cycle has faced 
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immense criticism for three of its key issues. These issues are its reliance upon a male model 
standard to determine female sexual normalcy, its assumption that sexual desire is a 
fundamental, inherent component of all sexual activity, and its reduction of female sexual desire 
to a strictly biological process unaffected by external sociocultural factors.  
The Human Sexual Response Cycle fails to differentiate between men and women’s 
sexual responses and instead suggests that they are one in the same. However, the Human Sexual 
Response Cycle was initially created to conceptualize the male sexual response (Wood, Koch, & 
Mansfield, 2006). Despite this, it has been utilized to exemplify healthy, normal sexual response 
for both men and women. Feminist literature has strongly critiqued this model for its male-
centered bias, which seems to suggest that women’s sexual experiences are normal only if they 
closely align with that of their male counterparts (Wood, Koch, & Mansfield, 2006).  Despite the 
problematic notions apparent in this model, and despite the fact that cis gender women do not 
necessarily follow this model in the ways that cis gender men do, this model has become 
dominant in discourse surrounding female sexual desire. (Wood, Koch, & Mansfield, 2006). By 
emphasizing the male-model standard of desire as the norm for both men and women, the 
medical community seems to suggest that failure to conform to male standards situates one 
beyond the realm of normalcy. If a man wants to have sex and his female partner does not, 
framing female desire in this way seems to suggest her lack of sex drive is abnormal; because 
men’s and women’s sexual responses are supposedly identical, any deviance from the prescribed 
norm exists as a dysfunction.  
Additionally, the Human Sexual Response Cycle situates desire as a precursor to sex, but 
as research reveals, women engage in sexual intercourse for myriad reasons that do not 
necessarily include sexual desire (O’Sullivan & Allgeier, 1998). The women who do so state that 
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they engage in sexual activity to satisfy a partner’s needs, to avoid rejecting a partner, to avoid a 
conflict, or to promote intimacy in the relationship (Impett & Peplau, 2002). While such reasons 
for pursuing sexual intercourse might be problematic due to the sense of obligation that these 
women feel, their reasons demonstrate that having sex and experiencing sexual desire are not 
necessarily concurrent. The Linearity model omits women’s feelings, portraying actions as the 
only important factor in determining desire.  
In addition to its focus on a male model standard and its failure to address the myriad 
reasons why women engage in sexual activity, feminist scholars have critiqued the biological 
conceptualization of desire for its reductionist focus on sexual desire as a phenomenon located 
within the body and for its focus on difference as disease (Tiefer, 1995; McCormick, 1994; 
Ussher, 1993). Scientific literature on female sexual desire renders women’s subjectivity 
invisible and casts them as the mere sites of quantitative processes. By framing desire as an 
entirely internal response, biological conceptualizations discount external contextual factors that 
might affect women’s urges to engage in sexual contact. As feminist scholar Leonore Tiefer 
notes, “[w]hen sexuality is seen primarily as a matter of health, research on biology 
predominates and is considered more central and definitive than research on sociocultural 
influences” (Tiefer, 1995). Framing desire itself as an entirely biological, internally driven 
response suggests that problems with desire also exist as biologically determined. Perhaps a 
woman with low libido has an exhausting, stressful job that entirely diminishes her sex drive. 
Perhaps she is simply no longer sexually attracted to her partner. Perhaps she just started 
watching a great new television show and would rather find out what happens in the next episode 
than have sex with her husband. The physiology and hormones of a woman with low libido 
might be perfectly fine; she could simply have other things going on in her life that render sex 
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unimportant or unappealing. This does not have to mean that she has a sexual dysfunction. As 
John Gagnon states, “[p]eople are not necessarily unhealthy or in need of medical treatment if 
they do not feel like having sex all the time” (Gagnon qtd in Fahs, 2011). All of this is not to 
suggest that biology plays no part in the creation of sexual desire, but rather to demonstrate how 
biological reductionism fails to address contextual or sociocultural factors that influence desire.  
Feminists have also critiqued biological conceptualizations of female sexual desire 
because they inherently situate sexuality under the rubric of health (Tiefer, 1995). The 
medical/health model for understanding desire relies upon the assumption that there exists a clear 
demarcation between healthy and unhealthy sexuality, but this is not the case; sexual normalcy 
varies depending on lifestyle, historical, and cultural variability (Fausto-Sterling, 2000). Despite 
the myriad problems associated with biological and medical conceptualizations of female sexual 
desire, this approach continues to dominate the field of sexual research and rhetoric regarding 
sexuality. The biomedical conceptualization of sexuality is often privileged over sociocultural 
conceptualizations because it seems to impart legitimacy and neutrality to claims that sex exists 
as a natural act and a healthy behavior, rather than a display of deviance or lack of self-control. 
Leonore Tiefer underscores this in her text Sex Is Not a Natural Act and Other Essays. Tiefer 
writes: 
The contemporary reason [why biological reductionism has retained a grip on sexology], 
the political one, has to do with legitimacy for sex research. Sex is dirty, or at least 
risqué, but emphasizing the biological basis makes it a more reputable subject of 
study…Biology’s privileged position within the contemporary sexuality discourse thus 
descended from early researchers’ hope that ‘objective science’ would replace oppressive 
orthodoxies of the past (Tiefer, 1995).  
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While biology’s alleged ability to provide objective proof as to why sex remains an important 
area of research appears beneficial, it ignores how physicians and scientists often construct 
sexual health norms based on cultural values rather than purely scientific sources (Tiefer, 1995). 
While some might argue that a biomedical lens for examining sexuality remains preferable to—
for example—religious doctrines that cast all sex outside of marriage as sinful, biomedicine 
similarly rigidly defines and attempts to constrict meanings of sexual normalcy—except 
seemingly unbiased, objective scientific evidence supports the latter. This biomedical gaze, 
according to Foucault, exerts social control over sexuality through both public health institutions 
and self regulation (Foucault, 1978). By pretending that sexuality is natural and biologically 
fixed, deviations from sexual norms are framed as threats to wellbeing and livelihood that 
require medical intervention.  
The Pharmaceutical Industry and Commodification of Feminism 
Pharmaceutical intervention is a key facet of biomedicine. Thus, casting perceived sexual 
problems as biological ailments suggests a need for a drug to treat them. As Leonore Tiefer 
states in her article “Female Sexual Dysfunction: A Case Study of Disease Mongering and 
Activist Resistance,” “[t]he public finds medicalization attractive because the notion of simple 
but scientific solutions fits in with a general cultural overinvestment in biological explanations 
and interventions, and promises to bypass sexual embarrassment, ignorance, and anxiety” 
(Tiefer, 2006). Tiefer’s statement demonstrates that pharmaceutical intervention seems to 
provide a seemingly simple way to meet sociocultural expectations of normalcy. However, 
pharmaceuticals do not actually address the root of the problem: the predominant belief that 
sexual normalcy exists and everybody is born understanding how to practice and achieve such 
normalcy. While some might argue that pharmaceutical intervention remains a positive force as 
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it addresses a sexual problem about which many women feel distressed, pharmaceutical 
intervention is hardly reflective of feminist ideals. Breanne Fahs notes this in her text Performing 
Sex. She writes, “ [w]hile feminism exists as a progressive force that tries to counter, circumvent, 
or smash the sexist practices that damage women in numerous ways, the pharmaceutical industry 
pushes a for-profit agenda that follows traditional ideas about gender norms by medicating 
women into compliance with appropriate femininity” (Fahs, 2011). Although the pharmaceutical 
industry often employs feminist rhetoric, such rhetoric is often a guise under which they produce 
and market their drugs. Ultimately, employing feminism to market a product that legitimizes 
patriarchal conceptualizations of sexual normalcy is antithetical to the feminist movement’s 
goals. The pharmaceutical industry’s portrayal of Flibanserin as fundamentally necessary for 
sexual equality exemplifies the insidious way that this industry employs feminist rhetoric to 
achieve some not-so-feminist ends. As previously discussed, Flibanserin ultimately achieved 
FDA approval as a result of its creators marketing it as a means to achieving sexual equality. 
This drug was said to be able to “level the playing field” and “even the score” between men and 
women, as though equality were a game that could be won with something as simple as a pill. 
Suggesting that sexual inequality can be cured with Flibanserin renders the deconstruction of 
social structures that contribute to discrimination unnecessary. While a quick fix for inequality is 
certainly attractive, Flibanserin merely reinforces and legitimizes the inequalities that already 
exist between men and women.  
While Flibanserin might be a proverbial beacon of hope for the women seeking to change 
their sex drive, this drug’s creators did not solely create this drug; they also helped to create and 
raise awareness about the disorder it intended to treat. In their article “Hypoactive sexual desire 
disorder: Inventing a Disease to Sell Low Libido,” Antoine Meixel, Elena Yanchar, and Adriane 
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Fugh-Berman assert that female sexual desire disorder exists as a fabricated illness constructed 
by pharmaceutical industries in order to make a profit. They discuss the ways in which the 
pharmaceutical industry offers continuing medical education (CME) courses to clinicians in 
order to establish a disease and increase clinician receptivity to new products. Their article 
identifies fourteen pharmaceutical industry–funded CME modules on hypoactive sexual desire 
disorder in women that predated the production of Flibanserin. These themes included the idea 
that “women may not be aware that they are sick or distressed” and the idea that “it is 
problematic that there are medicines available to treat sexual problems for men but not women” 
(Meixel, Yanchar, and Fugh-Berman, 2015). The former theme seems to suggest that women are 
not capable of identifying sexual dysfunction in themselves, stripping them of expertise over 
their own body and contrasting with the very definition of female sexual desire disorder outlined 
in the DSM-5. It also seems to suggest that anyone could possess this dysfunction, whether they 
recognize it or not. Flibanserin’s manufacturers suggesting that a woman might have a sexual 
disorder even without realizing it exemplifies a phenomenon outlined in Joseph Dumit’s text 
Drug’s for Life.  He underscores the ways in which the pharmaceutical industry has redefined the 
meaning of health. He writes, “health is no longer the silence of the organs; it is the illness that is 
silent, often with no symptoms” (Dumit, 2012). Because the body is always at risk for infirmity, 
consuming an ever-increasing number of drugs becomes an imperative. Suggesting to women’s 
doctors that their female patients are constantly at risk of sexual dysfunction has the potential to 
increase the number of women diagnosed with female sexual desire disorder and thus increase 
the number of people who will purchase Flibanserin. Redefining health and illness in this way 
simply allows for the pharmaceutical industry to make a profit.   
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As demonstrated in this section, the medicalization of women’s sexuality has historically 
worked to serve male interests. Even attempts to promote women’s sexual liberation often 
imposed standards that cast sexual inactivity as an inherent negativity and aligned—whether 
advertently or not—with male-centered beliefs about what normal sex should look like. The 
process of medicalization reaffirms this deeply embedded sociocultural belief that lack of sexual 
desire situates one beyond the realm of normalcy and legitimizes the taboos associated with 
sexual inactivity. Medicalization not only lends legitimacy to problematic conceptualizations of 
sexual normalcy, but also creates a myopic focus that renders sociocultural forces 
inconsequential to the formulation of sexual desire and encourages pharmaceutical intervention. 
This oversimplified portrayal of sexual desire suggests that not wanting to have sex is a health 
issue that can and should be changed through the consumption of drugs.  
PILOT RESEARCH 
This section thematically details how low female libido is conceptualized in medical and 
non-medical settings. I begin by analyzing the physical environments of the sexual health clinic 
and the adult entertainment store, demonstrating how these spaces act as a reflection of the 
approaches those who work within them use to understand sexual desire. I then examine the 
contrasting ways that the nurse practitioner and store manager respond to women’s anxieties 
about their low libido’s impact on their romantic relationships. This not only illuminates the 
ways that medical and non-medical settings differ in how they account for sociocultural 
influences, but also reveals the degree to which perceived relationship problems act as a catalyst 
for women to seek treatment for low libido. Finally, I explore the complex role that sexual 
pharmaceuticals play in these two settings. Inclusion of this material proves necessary as it paved 
the way for the guiding questions I decided to focus on in my interviews with women who have 
low libido.   
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The Physical Environments of the Clinic and Adult Entertainment Store 
The physical environment of the sexual health clinic and the adult entertainment store 
represented the most salient difference that set them apart. The clinic’s physical space was what 
one might expect from a doctor’s office; it had white, clean looking walls adorned with bland 
artwork and bright fluorescent lights lining the ceiling. Like most doctors’ offices, it was a rather 
cold, sterile environment. While such an environment is the standard for a clinical setting, it did 
not seem like a space that would make women feel comfortable enough to divulge information 
about their sex lives—information that Western society tends to characterize as taboo. 
Discussing sex in an environment typically associated with treating other physical ailments such 
as a sore throat or a bad back makes the act of sex appear incredibly clinical and detached from 
sociocultural influence. This highly sterile setting is seen as context free and suggests that sex is 
a physiological process uninfluenced by the sociocultural setting in which it is practiced. As 
feminist author Angela Carter notes, the notion that sex is an act uninfluenced by social context 
is gross, albeit common mischaracterization:  
Our flesh arrives to us out of history, like everything else does. We may believe we [have 
sex] stripped of social artifice; in bed, we even feel we touch the bedrock of human 
nature itself. But we are deceived. Flesh is not an irreducible human universal. Although 
the erotic relationship may seem to exist freely, on its own terms, among the distorted 
social relationships of a bourgeois society, it is, in fact, the most self-conscious of all 
human relationship, a direct confrontation of two beings whose actions in the bed are 
wholly determined by their acts when they are out of it (Carter, 1979). 
This is not to say that all sexual problems necessarily stem from social problems, but rather to 
demonstrate how medicalizing sex and discussing sex in the context of medicalized 
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environments seems to transform the act into a biological process that either works well or 
remains broken. Ignoring the sociocultural influences that shape sexual interactions does a major 
disservice to common understandings of sexualities. The physical setting of the adult 
entertainment store contrasted starkly with the physical space of the women’s health clinic. The 
store had colorful painted walls, warm lighting, upbeat music playing softly in the background, 
and adult products lining the walls and display tables. Overall, this space felt much more warm 
and inviting in comparison to that of the health clinic. While some might find this environment 
intimidating and the amount of products offered overwhelming, this setting appeared much more 
relaxed in comparison to the clinician’s office.  
Low Libido in the Context of Relationships 
The relationship between women seeking treatment for low libido and problems in their 
romantic partnerships is one of the primary themes I explored in this pilot work. When asked if 
women are ever prompted by boyfriends or husbands to seek medical intervention or if women 
ever complain about relationship problems that their low libido causes, the nurse practitioner 
stated that she “will not diagnose them [women with low libido] if they report it as a result of a 
problem in their relationship.” She went on to explain that women often express anxiety 
regarding the ways that low libido negatively impacts their romantic relationships. She asserted 
that as long as these relationship problems are not the reason these women seek treatment and 
they truly want to want more sex for themselves, then they can potentially receive medical 
intervention for their libido.  At first, this answer appeared straightforward, but as I transcribed 
the recording later that evening, I recognized how confusing it truly was. A woman cannot be 
diagnosed with FSDD if her low libido stems from an existing problem in her romantic 
relationship, but if low libido is causing a problem in her relationship, she could potentially 
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receive treatment for it. A woman can claim that she is not seeking treatment as a result of fear 
that her libido might damage her relationship, but if she reports that such a problem exists how 
can it be entirely overlooked within the diagnostic process? The nurse practitioner must trust 
what her patients say as she is unable to read her patients’ minds, but this still seems to 
underscore the existence of a metaphorical gray area within the medical arena. This not only 
demonstrates that women might pursue medical treatment for low libido because they fear its 
impacts on their relationship, but also reveals that such fear could play a role in the production of 
a medical problem.    
 The relationship between low libido and relationship problems in the context of the adult 
entertainment store contrasted starkly with its existence in the women’s sexual health clinic. 
After informing the manager of my project, I began to peruse the shelves to see how the products 
were advertised and displayed. While the store featured myriad products that were advertised as 
tools to enhance one’s sex life, those on display did not specifically mention women’s libido in 
relation to their romantic relationship. I then asked the manager if women are ever prompted by 
boyfriends or husbands to seek a “fix” for low libido. The manager responded by asserting that 
women approached her regarding libido enhancing products to help manage and prevent 
relationship issues “all the time.” She continued on to assert that she tells these women they 
should never have sex simply to appease a partner. Instead, she claimed that she asks these 
women about their levels of sexual satisfaction and offers advice and product recommendations 
with the potential to make sex an overall more enjoyable experience. She asserted that, “a lot of 
the time the sex these women do have isn’t really satisfying and you know, if these women have 
sex that they actually like, who knows- they might even start to want more of it.” The store 
manager’s response to these women demonstrates that she aims to help them by addressing what 
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she sees as a potential source of low libido, rather than suggesting that they have a medical 
problem. In contrast, the concept of sexual pleasure remained entirely absent from my 
conversation with the nurse practitioner; she made sex seem like a process unconcerned with 
physical enjoyment. In the medical arena, sex was just something that was supposed to happen 
without any acknowledgment for the context in which it occurs. The adult store’s manager saw 
pleasure as integral to any sexual encounter. According to her, finding ways to increase sexual 
desire proves useless until it is first established that these women are enjoying the sex they do 
have; the question should not be “how can I increase my sex drive?,” but rather “do I even enjoy 
the sex I do have?” Nobody wants to do things that causes themselves pain or discomfort and 
trying to increase libido without confronting the existence—or lack thereof—of pleasure is 
merely trying to convince women to conform to what is expected without accounting for their 
feelings. This suggests that sex is not about pleasure and mutual enjoyment for both parties as 
popular culture and media might lead one to believe, but is rather about getting something done 
and ticking a chore of a list.  
Low Libido and Sexual Pharmaceuticals 
My interview with the nurse practitioner yielded significant information regarding her 
opinions on Flibanserin and treating low libido with a pill more generally. The literature I 
reviewed prior to conducting this interview suggested that Flibanserin is a perilous drug that not 
only endangers women’s lives, but also fails to produce its intended results. In my conversation 
with the nurse practitioner, she asserted that she did prescribe the drug and that the women to 
whom she prescribes it typically report positive results. At one point, she even asserted that she 
has had women come in for follow-up appointments during which they cried tears of happiness 
over how much their libido had improved. It is, however, important to note that she testified to 
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the FDA on behalf of Sprout Pharmaceuticals, the pharmaceutical company that created 
Flibanserin, in order to demonstrate her support for the approval of the drug—suggesting that she 
might harbor biases that make her more inclined to prescribe it and speak highly of it.  
The information the nurse practitioner revealed regarding the supposed dangers of the 
drug revealed the sexist practices utilized to produce Flibanserin. Flibanserin’s warning label 
asserts that its interactions with alcohol can produce potentially life-threatening consequences. 
For that reason, women who take the drug—which is supposed to be taken every single day to 
prove effective—cannot consume any alcohol, acting as a deterrent that scares away potential 
consumers. When asked about these dangers, the nurse practitioner informed me that over 50% 
of the 11,000 women participating in Flibanserin’s clinical trial drank alcohol socially during its 
duration and that only six of the women reported episodes of hypotension and fainting as a result 
of alcohol use. Only one of these women required a hospital visit as a result of these side effects 
and this woman had a prior history of low blood pressure and fainting. Furthermore, the placebo 
group had 3 women who reported episodes of fainting and hypotension, making it difficult to 
discern whether or not the alcohol and drug combination existed as the source of such health 
issues. The nurse practitioner continued on to tell me that the FDA still thought that this was 
enough to place a ban on any alcohol consumption whilst taking Flibanserin. In order to ensure 
that women do not consume alcohol on the drug, they must sign a form stating such—a form that 
is then placed in their medical records.  
To ensure the accuracy of the nurse practitioners’ statements, I decided to look into the 
available alcohol-interaction research further. I discovered that the information the nurse 
practitioner had provided was somewhat misleading; this study is not the basis for the drug’s 
black box warning against alcohol. A black box warning refers to a warning that “appears on a 
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prescription drug’s label and is designed to call attention to serious or life-threatening risks” 
associated with the drug (A Guide to Drug Safety Terms at FDA, 2012).  The aforementioned 
data was deemed inconclusive, so Sprout Pharmaceuticals—the company manufacturing 
Flibanserin’s brand name counterpart Addyi—decided to conduct an alcohol safety study (Dahl, 
2015) This alcohol safety study was designed with FDA guidance and required that participants 
drink two to four shots of grain alcohol on an empty stomach within a timespan of ten minutes 
prior to taking the drug (Dahl, 2015). Not only does this study fail to reflect the actual 
circumstances in which a woman might consume alcohol and take this drug, the majority of the 
study’s participants were men. The study was comprised of 23 men and only two women (Risk 
Evaluation and Mitigation Strategy, 2015) Studying alcohol’s interaction with Flibanserin in men 
who take this drug proves useless, as this drug is not intended for and cannot be prescribed to 
men. Furthermore, using men as participants to study the interaction between this drug and 
alcohol potentially understates the complications that women could experience if they drink and 
take Flibanserin. It is commonly understood in the medical and scientific communities that 
women and men absorb and metabolize alcohol differently (Thomasson, 1995). Essentially, it is 
thought that women are more susceptible to alcohol’s effects than men. Because this study was 
done on men and found to have effects serious enough to warrant a complete ban on alcohol 
while taking the drug and because men are understood to have a higher tolerance for alcohol, the 
effects that drinking alcohol and taking this drug could have on women are potentially 
devastating. So not only is testing the alcohol interaction utilizing men entirely irrelevant, it also 
potentially endangers for women. Ultimately, it is unknown how women who take Flibanserin 
will react if they choose to drink alcohol, because no study has been conducted aiming to 
elucidate this interaction. This is an example of the way that women are continuously 
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underrepresented in biomedical research and the way that men remain the benchmark for sexual 
normalcy; this drug is not even intended for male consumption, yet more men than women were 
still selected to participate in trials testing the drug’s safety. Sprout’s CEO, Cindy Whitehead 
claimed that the reason this study used men was because they failed find female participants 
willing to take the drug and drink that much alcohol that quickly (Dahl, 2015). If that truly was 
the case, Sprout should have put the study on hold until female participants could be found. 
However, the pharmaceutical company clearly prioritized introducing the drug to market over 
the need to ensure accuracy regarding the drug’s safety and its affects on women. 
 In order to approach the theme of medicalization in the adult entertainment store, I asked 
the manager if she knew of any drugs available to treat low libido in women. She claimed that 
she was unaware of prescription drugs to treat this problem, but informed me that her store has 
herbal remedies for low female libido in stock. However, she did not speak highly of such 
remedies. She claimed that she deters customers from purchasing them and does not advertise 
their availability. Instead, she keeps them tucked away in a drawer behind the counter. She 
explained that she thinks the pills are merely caffeine pills that do nothing more than increase 
heart rate and induce a placebo effect. She asserted that she did not trust these pills—or any other 
pill—claiming to enhance libido. I then informed her about the creation of Flibanserin—a drug 
of which she had not previously heard. She conveyed anger and disappointment upon learning 
that a prescription drug to treat low female libido had been created. She stated that, “women 
should never have to take a pill to make them feel sexually normal. There’s no such thing as 
‘normal’ when it comes to sex”. The manager then gave me three of the low libido herbal 
supplements that her store carries.  
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The supplements’ packaging and names conjure imagery that reflects and reinforces 
sociocultural sexual expectations. These supplements are titled “JO FOR HER: LMAX NOW 
FEMALE PERFORMANCE,” “Kangaroo: Easy to Be A Woman Maximum Strength Sexual 
Enhancement,” and “Pandora: Unleash Her Inner Passion Sexual Enhancer for Women”. Two of 
the three supplements utilize depictions of animals in their packaging. The Jo For Her: Lmax 
Now Female Performance supplement is emblazoned with a panther splayed across a bright pink 
background. The Kangaroo: Easy to Be a Woman supplement contains a reference to Kangaroos 
in both its name and packaging. The allusion to animals suggests that sex is a basic, animalistic 
instinct. During sex, one apparently transforms from a human being into an instinct-driven, un-
restrained animal. Aside from the glaring problematic implications that this portrayal produces—
such as contributing to rape culture when specifically attributed to male sexuality by suggesting 
that men are powerless against sexual urges—portraying sex as an instinct based act in this 
context makes little sense. It suggests that sex is one of the most natural of all human urges, 
despite the fact that this supplement exists in order to induce this urge for those who lack it. This 
would then make the resulting sexual desire an unnatural byproduct by definition.  It is difficult 
to relate this directly to Flibanserin, as there have not been any television or print advertisement 
campaigns for this drug since its approval by the FDA. The mere existence of Flibanserin, 
however, speaks to the fact that the medical community has framed low libido as an abnormality.  
Additionally, listed directly under the Kangaroo supplement’s claim that this product 
makes it “easy to be a woman,” is a list of this product’s benefits. It states that this supplement 
creates better vaginal lubrication, lasts 72 hours, and creates intense orgasms. This suggests that 
being a woman necessitates intense orgasms, constant vaginal lubrication, and a constant 
willingness and need for sex. Women who fail to meet these qualifications are then not 
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considered actually “real” women. Furthermore, it also suggests that women alone are 
responsible for reaching orgasm in sexual encounters and that their sexual partners—who are 
assumed to be male due to the products use of a heterosexual couple on its packaging—play no 
part in women’s ability to climax. If a woman fails to have intense orgasms during sex, this 
product suggests that the best solution is consuming a pill, rather than communicating with her 
sexual partner about what might give her a higher degree of pleasure. And while advocating for 
women to experience more orgasms appears beneficial, the increased cultural emphasis on the 
necessity of the female orgasm has merely created an additional requirement that women must 
meet to achieve sexual normalcy. As Breanne Fahs notes, “[o]rgasms represent a synthesis of 
cultural performances women are expected to enact, for even those women who do not fake 
orgasms often claim that a great deal of performative effort goes into the production of them “ 
(Fahs, 2011). The female orgasm has become less about ensuring that heterosexual women are 
enjoying their sexual experiences and more about placating the male ego and assuring men that 
they have performed well. This forces women who are unable to reach climax in heterosexual 
sexual encounters to feel guilty as they feel as though their partner lacks visible proof of their 
sexual skill. Thus, a pill suggesting that “being a woman” necessitates that one have intense 
orgasms simultaneously reinforces and legitimizes yet another damaging, unrealistic demand for 
women’s sexuality as it pertains to men.  
The Pandora Sexual Enhancer for Women also relies on beliefs regarding what 
constitutes womanhood in its packaging, albeit in a slightly different manner. Written on the 
packaging in gold lettering is “Unleash Her Inner Passion,” suggesting that women’s sexual 
desires are like caged animals waiting to be set free from captivity. It is as if to say that, although 
women are stereotypically seen as reserved and restrained, immeasurable pent up sexual energy 
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bubbles just beneath their surfaces. This suggestion proves problematic, as it seems to convey 
that although a woman might claim not to want sex, such a desire exists deep down and simply 
requires coaxing. Additionally, the name Pandora seems to be a reference to Pandora’s box, an 
artifact in Greek mythology that was said to have contained all the world’s evil. Pandora opened 
the box, thereby releasing evil into the world. Utilizing Pandora’s box as a metaphor to represent 
the release of a woman’s sexual desire equates that desire to the release of evil. Irrespective of 
the manufacturer’s intent, this metaphor demonstrates that women’s sexuality is simultaneously 
sought after and seen as a threatening force.  
Although this pilot research revealed stark differences between the ways in which low 
libido is treated and responded to within medical and non-medical contexts, it also revealed the 
insidious ways that socially constructed ideas of sexual normalcy propel women to seek potential 
cures for perceived sexual abnormalities. Regardless of the context, not wanting to have sex was 
still confronted as a problem. However, the problematic portrayal of sexual inactivity and low 
libido did not begin in these two environments; these two environments are merely settings 
where this portrayal manifests. Because the problem did not start in the sexual health clinic or 
the adult entertainment store, they cannot be entirely dismantled there either. If a woman were to 
walk in to one of these two places asking for help to increase her sex drive and the nurse 
practitioner or the manager responded by telling her not to let socially constructed ideas of 
normalcy dictate how she feels about herself, I doubt that would do much to alter the anxiety she 
feels. While these two arenas certainly legitimize sexual norms—perhaps to different degrees—
and can potentially work to challenge them, this still does not reveal how women come to 
understand these norms in the first place.  Thus, this research prompted me to seek out women 
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with low libido in an attempt to understand how and why they came to see their sex drives as 
problems.  
SOCIOCULTURAL CONCEPTUALIZATIONS OF FEMALE AND MALE 
SEXUALITY: WHAT THE BIOMEDICAL APPROACH IGNORES 
As previously outlined, biomedical research regarding female sexual desire renders 
sociocultural influences invisible. The biomedical approach frames female sexuality utilizing an 
essentialist lens that conceals the patriarchal constructs in which women engage in heterosexual 
relationships. The interviews that I have conducted reflect the themes present within the 
sociocultural and feminist literature on female sexual desire and female sexuality more broadly. 
The women I interviewed share similar conceptualizations regarding the importance of romantic 
relationships, sex’s importance within the context of those romantic relationships, the male sex 
drive, and feelings about their own low libidos. These themes work to challenge current 
biomedical research and demonstrate that women’s low libidos are not the problem that requires 
change; it is the cultural expectations that women must meet that necessitate alteration.  
The Importance of Romantic Relationships 
Growing up, women are socialized to believe that romantic relationships are the pinnacle 
of interpersonal connection and that an absence of true love renders life incomplete. Beginning 
with fairytales in early childhood, women’s lives are inculcated with a restrictive notion of what 
it means to be a successful woman (Dworkin, 1974). In fairytales, a happily-ever-after requires 
finding true love. While most women do not see Cinderella or Sleeping Beauty as particularly 
powerful role models and generally relegate these stories to categories of childish fantasy, they 
are not the sole source of such notions. The idea of finding love in order to positively transform 
one’s life runs rampant in myriad media outlets. From magazines, to movies, to novels, the 
importance of romantic relationships is seemingly everywhere. While it appears simple to 
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dismiss the insidious messages that media perpetuate, as feminist scholar Jane M. Ussher notes, 
remaining completely immune to such messages proves difficult. She writes, “[m]ost women 
[claim to be immune to the media’s messages]: ‘I don’t believe what I read in women’s 
magazines,’ or ‘I take no notice of what I see on television,’ is perhaps the most common retort 
when questioned on the subject. It is often mine, too. But few of us are immune” (Ussher, 1997 
emphasis in original). Despite the fact that many recognize media portrayals of love as 
fabricated, these fabrications hold the power to affect one’s interpretation of the world. 
The women that I interviewed demonstrated the ways that the emphasis on finding 
romantic love permeates their lives and informs their understandings of what happiness requires. 
These women underscored a fear of being alone and a fear of remaining incapable of finding a 
romantic partner. One woman articulated fear about being unable to find “the one”. She stated, “I 
felt really terrible about my libido for a long time because I thought it, you know, might prevent 
me from, I guess, finding ‘the one’ or Mr. Right as silly as it sounds…I really do consider myself 
to be this independent feminist woman or whatever, but I still get worried” (Participant A). This 
participant’s comments reveal that although she recognizes how problematic and dubious the 
concept of one true love is, she remains incapable of denying the pressure she feels from these 
internalized patriarchal beliefs. Her quote reinforces Ussher’s assertion that it is immensely 
difficult to remain immune to the normative expectation and the perceived importance of finding 
love. Another participant similarly expressed her fear of being alone. This participant stated that 
she feels incredibly insecure that her partner may break up with her because of her low libido 
and that if he did, she could end up being alone forever since her libido keeps “ruining 
relationships” (Participant B). Her claims were reminiscent of feminist scholar Laura Kipnis’ 
discussions of marriage and love’s portrayal as the pinnacle of human achievement in American 
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culture and the most important thing to which one can aspire. Kipnis asserts that the modern self 
is “defined by love, an empty vessel without it” (Kipnis, 2003). This participant’s statements 
reflect Kipnis’ assertions; she defines herself and her happiness in relation to the presence of 
romantic love. It is crucial to recognize that it is romantic love, rather than friendship or familial 
love that retains such high levels of importance. Although her low libido is inconsequential in 
her non-romantic relationships, these forms of interpersonal connection pale in comparison to the 
supposed significance of romantic love.  
Furthermore, one participant explained the lengths she had gone to in order to avoid 
facing a break up. She explained how she had always felt that her low libido might be caused by 
the medication she takes. Her previous relationship began to have problems due to a lack of sex. 
She explained that she could sense that her partner was becoming increasingly unhappy and she 
wanted to try to boost her sex drive to appease him. However, she also asserted that she “did not 
even like this man very much,” but she wanted to be with him rather than be alone. Despite not 
even deeply caring for this man, she decided to switch medications to see if a change would 
benefit her sex drive—even though her previous medication had been working well to reduce the 
severity of her illness’s symptoms. This is not to say that deeply caring for her partner would be 
a suitable reason to change her medication and risk her health, but rather to highlight the fact 
that, for her, being in a relationship with someone she disliked was preferable to being single. 
Changing her medication sent her into an intense depression accompanied by suicidal ideation. 
She recognized that this was a result of the medication and after three weeks switched back to 
the drug she had formerly taken (Participant C). Her story reflects the concepts that both Ussher 
and Kipnis discuss; many women see singledom as an inherent negativity for which they will go 
to great lengths to avoid; being with any partner is far preferable to the alleged negativities 
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associated with singledom. Although she fortunately switched back to her former medication, the 
fact that she was even willing to risk her health in an attempt to ensure relationship stability 
underscores the level of importance she attributes to coupledom. 
Frequent Sex as the Foundation of a Healthy Relationship 
Sexual frequency is considered a foundational component of romantic partnerships, 
forcing those with low libido to view their sex drives as fundamentally inimical to a 
relationship’s success. In their text, The Gender of Sexuality feminist sociologists Pepper 
Schwartz and Virginia Rutter highlight sex’s increased importance. They assert, “[f]or both 
sexes, particularly in younger couples, the expectation of an extremely good, if not spectacular, 
sex life has become a common part of committed relationships…Sex is seen as the validation of 
the relationship, proof of the couple’s compatibility” (Rutter and Schwartz, 1998). Sex is not 
simply one facet of a relationship; it is understood to be a reflection of the relationship in its 
entirety. If a couple’s sex life is lackluster, it is said that that so too is the rest of their 
relationship. Despite overwhelming evidence suggesting that sexual frequency and sexual 
desire—particularly for women—tend to fade over the duration of couplehood, the portrayal of 
sex as a barometer for a relationship’s health persists (Rutter and Schwartz, 1998; Klusmann, 
2002; Ellwood-Clayton, 2012; Murray and Milhausen, 2012). Each couple wants to believe they 
are different and tends to operate under the belief that they will not be like those couples that 
stop having sex, despite the fact that the overwhelming majority of couples will experience 
decreased sexual frequency. The persistence of this idea seems to suggest that people are 
unaware that sexual frequency tends to diminish over time. However, this is not the case. One 
need only think of the popular joke about sexual frequency in marriage to recognize public 
understanding of sex as something that diminishes the longer a couple is together. Sexual 
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anthropologist Bella Ellwood-Clayton highlights this joke in Sex Drive: In Pursuit of Female 
Desire. She writes, “[I]f you were to put a marble in a jar every time you made love your first 
year of marriage, and then in your second year began to take a marble out every time, you’d 
never remove all the marbles from the jar” (Ellwood-Clayton, 2012). This demonstrates that 
cultural awareness of diminishing sexual frequency certainly exists, but because we are living in 
a time in which anything from television shows to physicians suggest that frequent sex is the key 
to happiness, the overemphasis on sex’s importance remains. This cultural preoccupation with 
sex as an exceedingly important component of romantic relationships seems to be attributed to 
the fact that men are said to be obsessed with sex and that making a relationship work requires 
their happiness to be prioritized above all else (Farvid and Braun, 2006; Ussher, 1997). Men are 
typically portrayed as afraid of commitment and uninterested in coupledom, so in order to entice 
them into settling down, women must consistently provide them with the thing they are said to 
care about above all else: sex. In theory, one might be able to recognize that this is little more 
than a ridiculous stereotype, but because these stereotypes have been hailed as truth for so long, 
it remains difficult to completely dismiss them. Furthermore, men and women continue to be 
rewarded—or punished—for behavior that either deviates from or conforms to these stereotypes. 
Men are praised for sleeping with lots of women, while women are praised for finding a new 
boyfriend or convincing her partner to “put a ring on it”.  
Each of the women I interviewed considered frequent sex to be an essential element of 
romantic partnerships. These women claimed that frequent sex has the ability to increase the 
overall intimacy between romantic partners and make other relationship issues less problematic. 
These women also underscored the anxiety they felt when they had not had sex with their 
partners for an extended period of time. For example, one participant stated, “I think sex is 
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important in a relationship and I feel anxious without having sex for too long because I feel we 
are neglecting our bonding experience and feel pressured to have sex because when you’re in a 
relationship there is a social stigma that you ‘have to’. However, if I were single, I would be very 
content without any sex at all” (Participant F). This participant’s comments highlight the way 
that the perceived importance given to sex in relationships frames sex as a job that needs to get 
done at all costs. She feels anxious not because she has a desire for sex that is not being met, but 
because she feels that bonding is hindered, if not entirely impossible, without sexual contact. For 
this woman, sex is not something done for the pleasure or mutual enjoyment of the parties 
involved, but is rather done in order to meet a quota. Failure to meet this arbitrary standard 
challenges the deeply ingrained notion that emotional intimacy necessitates sexual intimacy. By 
stating that she would be happy without ever having sex if she were single, she reveals that her 
low libido bothers her solely because it is said to threaten the bond she and her partner share and 
goes against sociocultural expectations for sex within a relationship.  
Another participant claimed that frequent sex improves a relationship’s chances at 
success because it renders other problems insignificant; relationship issues not related to sex can 
be overlooked in the presence of an active sex life. However, lack of sex merely amplifies other 
existing issues. This participant claimed that a couple can fight almost nonstop every single day, 
but as long as they have good sex—which she defined as frequent and satisfying—the other 
problems do not matter; being wildly sexually attracted to each other has the potential to sustain 
a relationship and make it successful (Participant C). Her comments seem to convey that sex is a 
panacea capable of remedying all relationship problems. This has deleterious implications: a 
good sex life does not necessarily indicate compatibility in other aspects of the relationship. 
Overlooking other relationship problems simply because the sex is great reinforces the notion 
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that sex is the absolute most important aspect of any romantic relationship. Furthermore, this 
demonstrates that it is impossible to disentangle concerns about low libido from concerns about 
one’s romantic relationship; because sex has been framed as a reflection of a relationship in its 
entirety, sexual problems fundamentally are relationship problems. The nurse practitioner from 
the women’s sexual health clinic had claimed that she will not prescribe Flibanserin if a woman 
reports that the distress about her low libido is because she feels it is a problem for her 
relationship, but her claim entirely disregards the fact that culturally, sex and relationships are 
portrayed as inherently intertwined.  
Perhaps the most salient example of the participants’ understanding of sex as 
fundamental to a relationship’s success and overall health came from Participant G. She stated 
that, “you know you have to do it [have sex] because it’s a huge part of a healthy relationship, 
but its just something you don’t want to do at all and it becomes more and more of a terrible 
thing for you” (Participant G). If being in a “healthy” relationship requires that a woman—or a 
partner of any gender—prioritize something that she does not want to do, perhaps that isn’t very 
healthy at all. Isn’t a relationship in which one partner must compromise their feelings just to 
meet some arbitrary sexual expectation unhealthier than one in which sex is happening less 
frequently if at all? While some degree of compromise is necessary in any type of relationship, 
romantic or otherwise, engaging in an act that one sees as “terrible” in order to stave off guilt and 
be able to meet societal expectations certainly does not seem beneficial. This relates to the 
aforementioned idea that romantic partnerships possess immeasurable importance and one 
should be willing to sacrifice anything in order to ensure their success. Each of these women 
reinforced the fact that sex is considered a benchmark for measuring relationship health. By not 
having frequent sex with their partners, these women harbored immense feelings of guilt and felt 
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that without frequent sexual contact their relationships were threatened. Despite the fact that they 
loved their partners very much and continued to engage in other forms of intimacy with them—
such as cuddling and handholding—lack of sex was consistently identified as a flaw that could 
engender a relationship’s demise if not addressed and fixed.  
Low Libido as a Problem Because it Negatively Affects Male Partners 
Current feminist literature reveals that many heterosexual women with low libido are not 
concerned with their lack of desire, but are rather concerned with the implications that their lack 
of desire poses for their relationships (Farvid & Braun, 2006; Hayfield & Clarke, 2012; Taylor, 
2015). In their 2012 study on sexual desire in heterosexual relationships, feminist scholars Nikki 
Hayfield and Victoria Clarke analyze data from their interviews with 10 British women. In these 
interviews, the women discussed sex and affection in their relationships (Hayfield & Clarke, 
2012). They discovered that all participants experienced a decrease in their desire over the course 
their monogamous relationships. Their research also revealed that these women were bothered 
by their decreased desire primarily because it bothered their male partners (Hayfield & Clarke, 
2012). This seems to challenge the very foundation upon which medicalized low libido has been 
built. The official disorder as described in the DSM-5 is characterized by low libido-induced 
distress. If a woman’s low libido is causing her distress, she can be said to have female sexual 
desire disorder and can potentially be prescribed Flibanserin. However, if these women are 
unconcerned with the symptoms of low libido and are instead concerned with its consequences 
for their relationship, providing Flibanserin in such instances seems to be an attempt to medicate 
women into conforming to their partners’ sexual desires.  
 The women I interviewed reinforced the findings in Hayfield and Clarke’s study; they all 
suggested that they were bothered by their low libidos solely because they felt their low libidos 
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negatively affected their male partners. When asked if their low libido caused distress and if so, 
what distressed them most about it, each participant framed her answer in terms of her libido’s 
effect on her partner. For example, one woman stated, “it does bother me. Recently my boyfriend 
said he wants to break up with me and I feel it’s because I rarely initiate sex” (Participant B). She 
also claimed that declining sex caused her to experience immense guilt. Following the 
conclusion of our interview, this woman sent me an email asking if I knew of any products 
available that could help to increase her sexual desire. This underscores her desperation to 
increase her libido; despite knowing that I am not a trained medical professional and am 
examining this alleged disorder from a sociocultural perspective, this participant still hoped I 
might be able to help alter her sex drive. Another participant stated that her low libido rarely 
crosses her mind while single; the only time it ever proves problematic or causes her distress is 
in a romantic partnership (Participant C). This is reminiscent of Participant F’s comments—both 
women explicitly stated that their libidos only bother them because they create relationship 
problems. These women are not bothered by low libido in and of itself, but are bothered by the 
fact that it makes it difficult to meet the alleged requirements necessary to be a good romantic 
partner. Each of the examples reinforces the findings outlined in Hayfield and Clarke’s study; 
women with low libidos see their sex drive as problematic because it contributes to relationship 
strain. In the absence of a relationship, low libido goes unnoticed. This entirely contradicts the 
DSM diagnostic criteria for female sexual desire disorder. The DSM criteria assert that women 
cannot be said to have this disorder if their distress about their libido stems from the fact that it 
causes relationship strain. However, as these women demonstrate, low libido is constituted as a 
problem solely in the context of relationships.  
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Furthermore, my research suggests that it is not just romantic relationships in general that 
cause women with low libido to feel distress, but romantic relationships specifically with men. 
Only two non-heterosexual women approached me to participate in my research. This initially 
indicated that low female libido is framed primarily as a heterosexual problem. The interview I 
conducted with one of my bisexual participants confirmed this. As previously explained, two of 
my participants identified as bisexual, however, only one of these women had actually had any 
sexual experiences with women. This woman explained that although her sex drive was just as 
low in her relationships with other women, she felt guilt and pressure about her low libido only 
in heterosexual relationships (Participant G). She claimed that her male partner never pressured 
her or made her feel bad about her low libido, yet her guilt persisted. When asked why this might 
be, she could not definitively pinpoint why she felt this way, but thought that it might have to do 
with the fact that men are said to have higher sex drives than women and that women are 
expected to do everything in their power to please their partners. She stated, “I guess it’s a 
mixture of the cultural messages that guys need more sex and that meeting their needs is the 
number one key to a successful relationship” (Participant G). Her response succinctly 
summarized why Flibanserin is not the feminist harbinger of equality that the pharmaceutical 
industry has dubbed it. Despite having low libido in both same sex and opposite sex relationships 
and despite the fact that her male partners never explicitly attempted to make her feel guilty 
about her libido, her guilt persisted solely in heterosexual relationships. If relationships between 
two women lack the tension that low libido contributes to in heterosexual relationships, then 
perhaps it is not low libido that exists as the source of the problem, but rather patriarchal 
heteronormativity’s rigid standards.  
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The aforementioned idea that men consistently desire more sex than women arose in 
several different interviews and seemed to be the source of the guilt that even women with 
understanding romantic partners felt about their low libidos. One woman explained that her 
partner was supportive and never pressured her to have sex, yet she still harbored guilt knowing 
he longed for an increased number of sexual encounters. She asserted that her inability to satiate 
his needs bothers her most about her libido (Participant D). Both Participants A and E expressed 
similar sentiments; despite having understanding partners, they continued to consider their low 
libidos a problem because they believed that their partners—and men in general—are always 
interested in having sex. The idea that men supposedly have higher sex drives by nature exists as 
the source of the persistent guilt that these women feel; they explained that men are simply more 
sexual than women (Participant A and Participant E). In Hayfield and Clarke’s study, the women 
commented on the role of media in suggesting that men require certain amounts of sex in order 
to be happy. Substantial research reinforces the idea that media portrays the male libido in a 
particular fashion; men are often depicted as being sex-obsessed and willing to do anything to 
“get it” (Ussher, 1997; Farvid and Braun, 2006). 
 The idea that men naturally have higher libidos than women was also apparent in my 
interview with Participant H. This woman claimed that despite the fact that her partner did not 
pressure her or attempt to make her feel bad about not wanting to have sex, her overwhelming 
guilt persisted. The guilt would be so overwhelming that, at times, she would “give in” and have 
sex despite not actually wanting to. When asked why she felt guilty about not wanting to have 
sex despite lack of pressure from her partner, she explained that she felt that men always want 
sex so even if her partner did not explicitly state it, that desire was still there. She stated, “I think 
men tend to be a bit more sex crazed than women...Like if the woman wants sex, the man will 
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always say yes. If a man wants sex the woman may say yes, but may say no” (Participant H). Her 
statements not only reflect sentiments similar to that expressed by the other participants 
regarding the male sex drive, they also point to a prominent, problematic sociocultural 
understanding of women as sexual gatekeepers. Men are understood to be in constant need of sex 
and simply waiting to hear yes from a woman. As Brianne Fahs notes, this notion “recklessly 
construct[s] women as merely the gatekeepers to men’s pleasure rather than sexual agents in 
their own lives” (Fahs, 2011). The woman-as-gatekeeper narrative is especially dangerous and 
suggests that women stand in the way of men’s ability to achieve sexual pleasure. Creating a pill 
intended to increase the female sex drive is simply an attempt to medicate women into aligning 
with patriarchal gender norms and an attempt to deconstruct some of the “obstacles” standing in 
the way of male pleasure.  This drug’s introduction in the medical arena reaffirms women’s fears 
that low libido is abnormal and needs to be “fixed”. Participant H, along with the other women I 
interviewed, reinforced the notion that men are seen as more sexual; although they thought of 
their partners as understanding, these women still felt that their boyfriends or husbands always 
desired additional sexual encounters and would never forego the opportunity to increase sexual 
frequency should such an opportunity present itself.  
CONCLUSION 
The biomedical approach for understanding female sexual desire strips women of their 
subjectivity and disregards the external contextual factors that influence sexual desire and 
women’s attitudes toward sex. This inadequate approach is the framework upon which the 
medicalization of female sexual desire disorder is predicated—demonstrating that the 
construction of low libido as a medical illness remains inherently problematic. While it is 
important to ensure that women receive the health care and the medical research that they desire, 
this does not mean that all health research is inherently positive. It is imperative to recognize the 
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patriarchal framework of the society in which medicalization occurs. Additionally, since 
portrayals of male sexuality suggest that men desire sex far more than their female counterparts 
and because women are socialized to believe that a successful relationship necessitates a 
confirmation to male sexual standards, women are often made to feel that it is their responsibility 
to have more sex than they desire to satiate a male partner’s needs. While feeling obligated to 
have sex to ensure a male partner’s happiness and to ensure a relationship’s success is 
problematic in and of itself, it is especially problematic considering that the drug to treat low 
libido is prescribed based almost entirely on the existence of distress; this seems to be an attempt 
to drug women so that they align with the standards of appropriate femininity. Physicians and 
nurse practitioners may claim that they will not prescribe Flibanserin if a woman’s distress about 
her libido is solely because she feels it threatens her relationship, but the ten women I 
interviewed demonstrate that the “problem” of low libido is constructed exclusively within 
romantic partnerships. Non-relationship related low libido distress does not even seem to exist.  
Furthermore, women are inundated with the message that being single renders happiness 
impossible and the idea that infrequent sex engenders a relationship’s demise—of course women 
with low libido are going to recognize their sex drive as a source of distress. Portraying 
Flibanserin as a tool for achieving sexual equality—as the pharmaceutical industry and 
prescribing physicians often do—is disingenuous at best and dangerous at worst, especially when 
myriad women want to induce desire to please their partners. That is not equality; it is merely a 
repackaging of oppressive ideals utilizing feminist rhetoric. While some might argue that it is 
paternalistic to suggest that all women are only seeking pharmaceutical intervention for low 
libido due to internalized misogyny, it is vital to recognize that women’s sexual development is 
always subject to sociocultural influence. Some women certainly do feel deeply distressed as a 
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result of their lowered sex drive, but perhaps the cure to such distress is not a pill, but rather a 
reconsideration of how we frame sex in our society.  
 In summation, my research reveals that not only is Flibanserin ineffective when it comes 
to supplementing sexual desire, but its existence is predicated on highly questionable 
assumptions regarding sexual normalcy and sexual expectations for women. The women I 
interviewed revealed that combating these expectations requires more than just recognition of 
their existence. Many of them explicitly asserted that they considered women’s sexual 
pharmaceuticals to be detrimental to women’s liberation and felt that the sexual expectations 
imposed upon women were unfair, yet could not deny their desire to increase their libidos in an 
attempt to remedy relationship problems. This demonstrates that simply being aware of sexual 
inequality does little to change the reality of the expectations for interpersonal, romantic 
relationships between men and women. A woman can be a self-proclaimed feminist, but 
subverting the sociocultural demands expected of her within opposite-sex relationships becomes 
increasingly complex behind closed doors and in between the sheets. The medical and scientific 
communities’ failure to confront assumptions regarding sexual normalcy has resulted in the 
creation of a drug that legitimizes low libido as a medical disorder and sociocultural sexual 
expectations, yet does little to fix the perceived problem. However, this is not to say that creating 
an improved version of Flibanserin that actually augments female libido would engender 
positive, transformative change. Focusing research efforts on creating new drugs to increase 
women’s sexual desire is a misplacement of energy and resources and attempts to provide an 
answer to what I argue is the wrong question. The question should not be “how can we make 
women want more sex,” but should instead be “how can we dismantle the unrealistic 
expectations women feel they must meet in order to be considered normal?” I do not claim to 
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know the answer to this question—and perhaps a definitive answer does not exist—but actually 
listening to women’s narratives about their own low libidos seems like a positive starting point.  
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